IGC Pharma (DE:IGS1)
FRANKFURT:IGS1
| Mar 26 | Mar 25 | Mar 24 | Jun 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.19M | $ 1.27M | $ 1.34M | $ 911.00K | $ 397.00K |
| Gross Profit | $ 352.00K | $ 619.00K | $ 733.00K | $ -158.00K | $ 194.00K |
| Operating Income | $ -10.20M | $ -7.45M | $ -9.80M | $ -11.57M | $ -15.43M |
| EBITDA | $ -9.88M | $ -6.98M | $ -9.16M | $ -10.85M | $ -14.37M |
| Net Income | $ -6.55M | $ -7.12M | $ -13.00M | $ -11.51M | $ -15.02M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 207.00K | $ 405.00K | $ 1.20M | $ 3.35M | $ 10.46M |
| Total Assets | $ 9.19M | $ 8.75M | $ 9.90M | $ 17.18M | $ 26.83M |
| Total Debt | $ 0.00 | $ 238.00K | $ 348.00K | $ 481.00K | $ 611.00K |
| Net Debt | $ -207.00K | $ -167.00K | $ -850.00K | $ -2.71M | $ -9.85M |
| Total Liabilities | $ 3.06M | $ 2.42M | $ 2.58M | $ 2.27M | $ 2.94M |
| Stockholders' Equity | $ 6.12M | $ 6.33M | $ 7.32M | $ 14.91M | $ 23.89M |
| Cash Flow | |||||
| Free Cash Flow | $ -6.11M | $ -5.28M | $ -5.71M | $ -7.67M | $ -8.23M |
| Operating Cash Flow | $ -5.94M | $ -4.79M | $ -5.20M | $ -7.05M | $ -7.46M |
| Investing Cash Flow | $ -192.00K | $ -442.00K | $ -317.00K | $ -235.00K | $ -742.00K |
| Financing Cash Flow | $ 5.93M | $ 4.45M | $ 3.52M | $ 100.00K | $ 4.14M |